Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) EBITDA (2016 - 2025)

Pediatrix Medical (MD) has disclosed EBITDA for 17 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 14.28% to $33.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.1 million, a 270.61% increase, with the full-year FY2025 number at $167.1 million, up 270.61% from a year prior.
  • EBITDA was $33.8 million for Q4 2025 at Pediatrix Medical, down from $72.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $72.0 million in Q3 2025 to a low of -$152.8 million in Q2 2024.
  • A 5-year average of $13.7 million and a median of $27.0 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 647.86% in 2024, then soared 425.42% in 2025.
  • Pediatrix Medical's EBITDA stood at $68.0 million in 2021, then tumbled by 55.85% to $30.0 million in 2022, then plummeted by 509.61% to -$123.0 million in 2023, then surged by 124.08% to $29.6 million in 2024, then increased by 14.28% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for MD's EBITDA are $33.8 million (Q4 2025), $72.0 million (Q3 2025), and $39.7 million (Q2 2025).